ABSTRACT
Recurrent pregnancy loss (RPL) affects around 2% of women of reproductive age. Primary RPL is defined by ≥2 pregnancy losses and no normal birth delivery. In secondary RPL, the losses are after a normal pregnancy and delivery. Most cases have no clear aetiology, although primary cases are the most complex. Several gene single nucleotide polymorphisms (SNPs) have been associated with RPL. The frequency of some SNPs is increased in women suffering from RLP from Asian or Caucasian races; however, in admixed populations, the information on possible genetic links is scarce and contradictory. This study aimed to assess the frequency of two SNPs present in two different enzymes involved in medical conditions observed during pregnancy. It is a case-control study. Microsomal epoxy hydrolase (mEPH) is involved in detoxifying xenobiotics, is present in the ovaries, and is hormonally regulated. The endothelial nitric oxide synthase (NOS3) that forms nitric is involved in vascular tone. Two SNPs, rs1051740 (mEPH) and rs1799983 (NOS3), were assessed. The study included 50 controls and 63 primary RPL patients. The frequency of mutated alleles in both SNPs was significantly higher in patients (p < 0.05). Double-mutated homozygotes were encountered only in RPL patients (p < 0.05). Genetic polymorphisms rs1051740 and rs1799983 may be involved in primary RPL in the Venezuelan admix population. Genetic studies could provide crucial information on the aetiology of primary RPL.
ABSTRACT
ADAM33 es una metaloproteinasa de la matriz extracelular involucrada en la remodelación tisular y, por ello, en el asma y la enfermedad pulmonar obstructiva crónica (EPOC). Se han reportado varios polimorfismos del gen de ADAM33 asociados a la actividad enzimática. Los polimorfismos más estudiados son el V4, citosina por una guanina en la región 3 UTR, y el T1, adenina por una guanina en el exón 19 del gen. El objetivo del presente trabajo fue determinar la posible asociación de los polimorfismos de nucleótido simple de ADAM33, V4 y T1, con la presencia de asma o EPOC en pacientes venezolanos. Los polimorfismos V4 y T1 fueron analizados en 303 individuos (103 asmáticos, 100 EPOC, y 100 controles) mediante PCR-RFLP (reacción en cadena de la polimerasa y análisis de polimorfismos por longitud de fragmentos de restricción enzimática). La frecuencia genotípica del polimorfismo V4 fue significativamente mayor (p<0,05) en ambos grupos de pacientes, asmáticos y EPOC, con respecto al control. No se encontraron diferencias significativas (P=0,4) en el polimorfismo T1. Sin embargo, se evidenció una diferencia significativa (p<0,05) cuando los haplotipos y diplotipos de ADAM33 V4/T1 se compararon entre los tres grupos. Se concluye que el polimorfismo ADAM33 V4 está asociado con la presencia de asma o EPOC en pacientes venezolanos.
ADAM33 is a metalloproteinase important in the extracellular matrix for tissue remodeling, and, consequently, in asthma and chronic obstructive pulmonary disease (COPD). Several polymorphisms of the ADAM33 gene have been associated with enzyme activity. One of the most studied polymorphisms is V4, cytosine for guanine in the 3UTR region, and T1, adenine for guanine in the exon 19 of the gen. The aim of this study was to ascertain the possible association among single polymorphisms of ADAM33, V4 and T1, in Venezuelan patients with asthma or COPD. The polymorphisms V4 and T1 were analyzed in 303 individuals (103 asthmatic, 100 COPD and 100 controls) by PCR-RFLP (polymerase chain reaction and restriction fragment length polymorphisms). There was a significant difference (P<0.05) in the frequency of ADAM33 V4 polymorphism in both, asthmatic and COPD patients groups, as compared to controls. No significant differences (P=0.4) were found for T1 polymorphism. However, there were significant differences (P<0.05) when haplotypes and diplotypes of ADAM33 V4/T1 were compared in all three groups. It can be concluded that the polymorphism V4 of ADAM33 is associated with asthma or COPD in Venezuelan patients.
Subject(s)
Adult , Female , Humans , Male , Middle Aged , Asthma/genetics , Polymorphism, Single Nucleotide , Pulmonary Disease, Chronic Obstructive/genetics , ADAM Proteins/genetics , VenezuelaABSTRACT
ADAM33 is a metalloproteinase important in the extracellular matrix for tissue remodeling, and, consequently, in asthma and chronic obstructive pulmonary disease (COPD). Several polymorphisms of the ADAM33 gene have been associated with enzyme activity. One of the most studied polymorphisms is V4, cytosine for guanine in the 3 'UTR region, and T1, adenine for guanine in the exon 19 of the gen. The aim of this study was to ascertain the possible association among single polymorphisms of ADAM33, V4 and T1, in Venezuelan patients with asthma or COPD. The polymorphisms V4 and T1 were analyzed in 303 individuals (103 asth- matic, 100 COPD and 100 controls) by PCR-RFLP (polymerase chain reaction and restriction fragment length polymorphisms). There was a significant difference (P<0.05) in the frequency of ADAM33 V4 polymorphism in both, asthmatic and COPD patients groups, as compared to controls. No significant differences (P=0.4) were found for T1 polymorphism. However, there were significant differences (PSubject(s)
ADAM Proteins/genetics
, Asthma/genetics
, Polymorphism, Single Nucleotide
, Pulmonary Disease, Chronic Obstructive/genetics
, Adult
, Female
, Humans
, Male
, Middle Aged
, Venezuela
ABSTRACT
The use of vaccines in pregnant, immunocompromised or chronic diseases patients has been widely discussed in the literature recently. Vaccines continue to be a safe and effective method to induce or recall immune response to several infective agents or even induce an effective response in chronically infected patients. The general presumption of adverse events, lack of response and unwanted tolerance seem to be responsible for the decreased vaccination rate in these patients. In the present review, the use of rational vaccination schemes, new patents of use, along as new approaches and patents have been discussed with the scope to diminish the high morbidity and mortality often encountered in these patients.
Subject(s)
Immunocompromised Host/immunology , Pregnancy/immunology , Vaccines/immunology , Chronic Disease , Female , Humans , VaccinationABSTRACT
BACKGROUND: One of the gene polymorphisms often studied in asthmatic patients is the ß2 adrenergic receptor (ADRß2). Even though in the Venezuelan Mestizo population there is a high incidence of asthma, there are no direct reports of ADRß2 gene polymorphism, and treatment response. The aim of this study was to assess, in this population, the gene frequency of ADRß2 polymorphisms at codons 16 Arg/Gly and 27 Gln/Glu, allergen sensitization, and its relationship to bronchodilator response. METHODS: Purified genomic DNA was obtained form 105 Mestizo asthmatic and 100 Mestizo healthy individuals from Venezuela. The two polymorphisms were assessed by PCR-RFLP. Patient sensitization to aeroallergens and their response to bronchodilatation were correlated. RESULTS: Significant differences between patients and controls were recorded in: 1) the prevalence of Arg/Arg at codon 16 (28.6% in patients vs. 47% in controls, P<0.01), 2) the frequency of heterozygotes Arg/Gly (55% in patients vs. 35% in controls, P<0.01). Conversely, no differences in polymorphism frequencies were found at codon 27. The haplotypes Arg/Gly-Gln/Gln were more common in patients than controls (P <0.01), whereas the Arg/Arg-Gln/Glu combination prevailed in the control group (P<0.01). The Arg/Gly and Gln/Glu genotypes were associated with better responses after salbutamol. The asthmatic homozygotes Arg/Arg have higher sensitivity to aeroallergens. CONCLUSION: The difference in Arg/Arg frequency between groups suggests that this could be a protective genotype although the asthmatic group had a higher sensitivity to aeroallergens. The asthmatic heterozygotes had better bronchodilator responses than the homozygotes.
Subject(s)
Asthma/drug therapy , Asthma/genetics , Bronchodilator Agents/therapeutic use , Polymorphism, Genetic , Receptors, Adrenergic, beta-2/genetics , Adult , Codon/genetics , Female , Humans , Male , VenezuelaABSTRACT
La sensibilización y las manifestaciones alérgicas al maní se han incrementado últimamente a nivel mundial, constituyendo el mismo la causa principal de anafilaxia por alimentos. Como la prevalencia de alergia al maní varía de acuerdo a las regiones nos propusimos evaluar, en una etapa preliminar, la sensibilización al maní por pruebas cutáneas (skin prick test) en pacientes venezolanos atópicos y/o con urticarias que acudieron a la Consulta ambulatoria de Alergía del Instituto de Inmunología. El 5,4 % de los pacientes manifestó algún tipo de manifestación cutánea o respiratoria al ingerir maní. Se demostró sensibilización al maní por pruebas cutánea en el 6,5 % de los pacientes. Sin embargo, un porcentaje pequeño (2 %) de ellos mostró, en conjunto, pruebas cutáneas positivas y síntomas a la ingesta del maní. Ningún paciente refirió síntomas severos tras la ingestión de maní. La mayoría de los pacientes con pruebas positivas al maní, también mostraron pruebas positivas a otros alimentos. Estos resultados concuerdan con la percepción de los médicos venezolanos de una baja frecuencia de reacciones adversas, especialmente graves, a la ingesta de maní en nuestro país
Peanut allergy and sensitization incidence has increased world wide to become the first cause of food anaphylaxis. Since the prevalence of peanut allergy changes according to geographical areas, the aim of the study was to assess, in a preliminary report, peanut allergy incidence by skin prick test in atopic Venezuelan patients with atopy and or urticaria from the outpatient allergy clinic of the Institute of Immunology. Cutaneous or respiratory manifestations after peanut ingestion was observed in 5.4 % of the patients studied. Cutaneous test was positive in 6.5 % of patients. In the other hand, a small group (2 %), showed positive skin test along with symptoms after peanut ingestion. None of the patients had severe reactions. Most of the patients with peanut positive skin test were positive to other food allergens. These results are in accordance with the general clinical perception of small frequency of adverse reaction, specially the most serious ones, to peanut ingestion in our country
Subject(s)
Humans , Male , Female , Child, Preschool , Child , Adolescent , Young Adult , Arachis/adverse effects , Arachis/immunology , Food Hypersensitivity/immunology , Food Hypersensitivity/pathology , Immunologic Tests/methods , Urticaria/immunology , Urticaria/pathology , Allergy and ImmunologyABSTRACT
Endometriosis is an inflammatory disease characterized by the presence of endometrial glandular epithelial and stromal cells growing in the extra-uterine environment. The disease affects: ovarian function, oocyte quality, embryo development and implantation, and uterine function resulting in infertility or spontaneous pregnancy loss. Even though the world's prevalence is above 10 %, an effective treatment has not yet been found. New pharmacological approaches have been designed and patented that could serve as future therapies for this disease.
Subject(s)
Drug Discovery/methods , Endometriosis/drug therapy , Women's Health/trends , Drug Design , Female , Humans , Patents as TopicABSTRACT
Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized mainly by pulmonary airflow limitation that is not fully reversible. New different pharmacological approaches to decrease inflammation of the airways and consequently disease progression and increase airway obstruction reversibility have been developed. In the present article, we review the new patents on phosphoinositide 3 kinase and NFκb inhibitors for future therapies.
Subject(s)
Anti-Inflammatory Agents/therapeutic use , Imidazolines/therapeutic use , NF-kappa B/antagonists & inhibitors , Phosphoinositide-3 Kinase Inhibitors , Pulmonary Disease, Chronic Obstructive/drug therapy , Steroids/therapeutic use , Animals , Anti-Inflammatory Agents/pharmacology , Humans , Imidazolines/pharmacology , Patents as Topic , Steroids/pharmacology , TOR Serine-Threonine Kinases/antagonists & inhibitorsABSTRACT
The present work was intended to study the process of fibrin formation and lysis and plasmin generation in a group of patients with recurrent miscarriage (RM), due to the presence of antiphospholipid antibodies (N = 10); as well as in women with RM without the antiphospholipid syndrome (APS) (N = 6), compared with those of a group of healthy women (N= 8). In the group of patients with APS, nine were positive for antibodies against cardiolipin (aCL), five for anti-beta2-glycoprotein I (anti-beta2GPI), four for both antibodies, and one for antibodies against prothrombin (aPT) and lupus anticoagulant (LA). Fibrin formation and lysis was followed by turbidity and plasmin generation using chromogenic substrate S2251. The polymerization curves from RM patients without APS and the LA patient showed an increased slope and maximum turbidity compared to those of the control group. The speed of lysis was higher in the LA patient (21 +/- 0) 10(-4) deltaOD/seg and the RM patients without APS (19.6 +/- 5.7) 10(-4) deltaDO/seg, compared to that of the control group (14.5 +/- 2.8) 10(-4) deltaDO/seg. Plasmin generation increased only in RM patients without APS (85 +/- 24%) against the control group (52 +/- 3%), p = 0.005. The changes observed in the fibrin polymerization and lysis process of women with RM without APS and LA seem to be related to their higher fibrinogen levels, while the increased plasmin generation was related to the patients' morbidity.
Subject(s)
Abortion, Habitual/blood , Antibodies, Antiphospholipid/immunology , Antiphospholipid Syndrome/blood , Fibrin/metabolism , Fibrinolysin/biosynthesis , Abortion, Habitual/immunology , Adult , Antibodies, Anticardiolipin/immunology , Antiphospholipid Syndrome/immunology , Autoantigens/immunology , Biopolymers , Blood Coagulation/physiology , Enzyme Activation/drug effects , Female , Fibrinolysis/physiology , Humans , Lupus Coagulation Inhibitor/blood , Nephelometry and Turbidimetry , Plasminogen/metabolism , Pregnancy , Streptokinase/pharmacology , Thrombin/biosynthesis , Thrombophilia/etiology , Young Adult , beta 2-Glycoprotein I/immunologyABSTRACT
BACKGROUND: Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized mainly by pulmonary airflow limitation that is not fully reversible. The airflow limitation is usually progressive and associated with abnormal inflammatory response of the lung to noxious particles or gasses. New different pharmacological approaches to decrease inflammation of the airways and consequently disease progression and increase airway obstruction reversibility have been developed. METHODS AND RESULTS: A literature search using PubMed, Science Direct, EBSCO and free patents on line for the years 2000-2010. CONCLUSIONS: Recent discoveries in the physiology and pathology of airways diseases have served to generate potential new drugs for the treatment of COPD patients. Several substances that block or activate specific pathways and receptors the aim of which is to decrease inflammation and increase airway obstruction reversibility are being used in different clinical protocols and hopefully will be available for patients in the near future.
Subject(s)
Pulmonary Disease, Chronic Obstructive/drug therapy , HumansABSTRACT
En el presente trabajo se estudió el proceso de formación y disolución de la malla de fibrina y la generación de plasmina en un grupo de pacientes con aborto recurrente (AR) debido a la presencia de anticuerpos antifosfolipídicos (N= 10), mujeres con AR sin el síndrome antifosfolipídico (SAF) (N= 6) y se comparó con un grupo de mujeres sanas (N= 8). Del grupo de pacientes estudiadas con SAF, nueve fueron positivas para anticuerpos anticardiolipina (aCL), cinco para la anti-b2-glicoproteína I (anti-b2GPI), cuatro para ambos anticuerpos, una para anticuerpos antiprotrombina (aPT) y anticoagulante lúpico (AL). El proceso de formación de la fibrina y su disolución fue estudiado por turbidimetría y la generación de plasmina mediante sustrato cromogénico S2251. Las curvas de polimerización de la(s) paciente(s) con AR sin SAF y AL presentaron un incremento en la pendiente y turbidez final, comparado con las del grupo control de mujeres sanas. La velocidad de disolución del coágulo fue mayor en la paciente con AL (21 ± 0) 10-4 DDO/seg y en las AR sin SAF (19,6 ± 5,7) 10-4 DDO/seg, comparado con el grupo control (14,5 ± 2,8) 10-4 DDO/seg. La generación de plasmina estuvo incrementada solamente en las AR sin SAF (85 ± 24%) comparado con 52 ± 3% en el grupo control, p= 0,005. Los cambios observados en el proceso de polimerización y fibrinólisis de la(s) paciente(s) con AR sin SAF y AL pudieran estar relacionados con el incremento en los niveles de fibrinógeno, mientras que los de la generación de plasmina con la entidad mórbida.
The present work was intended to study the process of fibrin formation and lysis and plasmin generation in a group of patients with recurrent miscarriage (RM), due to the presence of antiphospholipid antibodies (N= 10); as well as in women with RM without the antiphospholipid syndrome (APS) (N= 6), compared with those of a group of healthy women (N= 8). In the group of patients with APS, nine were positive for antibodies against cardiolipin (aCL), five for anti-b2-glycoprotein I (anti-b2GPI), four for both antibodies, and one for antibodies against prothrombin (aPT) and lupus anticoagulant (LA). Fibrin formation and lysis was followed by turbidity and plasmin generation using chromogenic substrate S2251. The polymerization curves from RM patients without APS and the LA patient showed an increased slope and maximum turbidity compared to those of the control group. The speed of lysis was higher in the LA patient (21 ± 0) 10-4 DOD/seg and the RM patients without APS (19.6 ± 5.7) 10-4 DDO/seg, compared to that of the control group (14.5 ± 2.8) 10-4 DDO/seg. Plasmin generation increased only in RM patients without APS (85 ± 24%) against the control group (52 ± 3%), p= 0.005. The changes observed in the fibrin polymerization and lysis process of women with RM without APS and LA seem to be related to their higher fibrinogen levels, while the increased plasmin generation was related to the patients´ morbidity.
Subject(s)
Adult , Female , Humans , Pregnancy , Young Adult , Abortion, Habitual/blood , Antibodies, Antiphospholipid/immunology , Antiphospholipid Syndrome/blood , Fibrin/metabolism , Fibrinolysin/biosynthesis , Abortion, Habitual/immunology , Antibodies, Anticardiolipin/immunology , Antiphospholipid Syndrome/immunology , Autoantigens/immunology , Biopolymers , Blood Coagulation/physiology , Enzyme Activation/drug effects , Fibrinolysis/physiology , Lupus Coagulation Inhibitor/blood , Nephelometry and Turbidimetry , Plasminogen/metabolism , Streptokinase/pharmacology , Thrombin/biosynthesis , Thrombophilia/etiology , /immunologyABSTRACT
a exposición ocupacional al látex incrementa el riesgo de sensibilización al mismo en los profesionales de la salud. El objetivo de este estudio ha sido establecer la prevalencia de la alergia y de la sensibilización al látex en una población conformada por los estudiantes de postgrado de la Facultad de Odontología de la UCV e identificar los posibles factores de riesgo. Pacientes y métodos: Se realizó un cuestionario sobre actividad laboral y antecedentes de síntomas y reacciones alérgicas. También se diagnosticó la hipersensibilidad tipo I mediante la prueba cutánea por técnica de "prick test" como prueba in vivo y un método ELISA utilizando el ENEASystem III como prueba in vitro. Resultados: Estas dos pruebas diagnósticas arrojaron un total de un 32% (27) participantes con hipersensibilidad tipo I al látex. Referente a los factores considerados como de riesgo, 33% (9) de estos pacientes sensibilizados tenían antecedentes familiares de alergia; 44% (12) reportaron antecedentes personales de alergia y 59% (16) habían sido sometidos a intervenciones quirúrgicas. Del total de los individuos sensibilizados al látex 56% (15) manifestaron síntomas respiratorios o cutáneos al entrar en el área odontológica.Conclusiones: En este estudio se encontró una elevada prevalencia de hipersensibilidad tipo I al látex (32%) en los estudiantes de postgrado de la Facultad de Odontología de la UCV, siendo necesario, a futuro, aclarar si esta tendencia se mantiene en un grupo mas heterogéneo (odontólogos y su personal auxiliar)
Occupational exposure increases the risk of latex sensitization in health professionals. The aim of this study was to establish the prevalence of allergy and latex sensitization in graduate students of the Faculty of Dentistry of the Universidad Central de Venezuela and to identify possible risk factors. Patients and methods: We conducted a questionnaire on work activity, history of symptoms and allergic reactions. We diagnosed type I hypersensitivity by skin test as evidence in vivo and an ELISA using ENEASystem III as evidence in vitro. Results: 32% (27) participants were diagnosed with type I hypersensitivity to latex, 33% (9) of sensited participants had family history of allergy, 44% (12) reported a history of allergy and 59% (16) had undergone surgery. Of all patients sensitized to latex 56% (15) reported respiratory symptoms or skin to enter the dental area.Conclusions: This study found a high prevalence of type I hypersensitivity to latex (32%) in students of the Faculty of Dentistry, in future, need to clarify whether this trend continues in a more heterogeneous group (dentists and their staff)
Subject(s)
Humans , Male , Female , Dermatitis, Contact , Dermatitis, Occupational , Latex Hypersensitivity , Occupational Health , Education, Dental, GraduateABSTRACT
Los niveles séricos de la metaloproteinasa (MMP) 9, enzima involucrada en inflamación, y su contraparte, el inhibidor tisular de la metaloproteinasas tipo 1 (TIMP-1), se encuentran significativamente (P < 0,01) incrementados en pacientes con asma o con enfermedad pulmonar obstructiva crónica (EPOC) en comparación con los grupos control del mismo rango etario. El incremento de ambos parámetros se hace más significativo en los pacientes severos de ambos grupos (P < 0,0001) y particularmente en los pacientes con EPOC severo en comparación con los asmáticos severos (P < 0,01). El incremento en los niveles séricos de MMP-9 en relación con severidad es mayor que lo observado para TIMP-1 en ambas patologías. Se concluye que los niveles séricos de MMP-9 y TIMP-1 pueden ser un marcador importante para determinar severidad en estas enfermedades
Serum levels of metalloproteinase (MMP) 9, an enzyme involved in inflammation, and its counterpart, the tissue inhibitor of metalloproteinases type 1 (TIMP-1) are significantly (P < 0.01) increased in patients with asthma or with chronic obstructive pulmonary disease (COPD) as compared with controls of the same age. The increase in both parameters is more significant (P < 0.0001) in severe patients of both groups, and particularly in patients with severe COPD as compared to severe asthmatics (P < 0.01). The increase in serum MMP-9 levels in relation with severity is higher than the observed values for TIMP-1 in both diseases. It is concluded that serum levels of MMP-9 and TIMP-1 may be important markers to establish severity in these diseases
Subject(s)
Humans , Male , Female , Asthma/diagnosis , Pulmonary Disease, Chronic Obstructive/diagnosis , Tissue Inhibitor of Metalloproteinase-1/analysis , Biomarkers/analysis , Biomarkers/blood , Matrix Metalloproteinase 9/analysis , Allergy and ImmunologyABSTRACT
Thalidomide and its immunomodulatory imide drugs (IMiDs) analogues CC-5013 (Revlimid, Lenalidomide) and CC-4047 (Actimid, Pomalidomide) have been used as anti-inflammatory and anticancerous drugs in the recent years. Thalidomide and IMiDs inhibit the cytokines tumour necrosis factor-alpha (TNF-alpha), interleukins (IL) 1-beta, 6, 12, and granulocyte macrophage-colony stimulating factor (GM-CSF). They also costimulate primary human T, NKT and NK lymphocytes inducing their proliferation, cytokine production, and cytotoxic activity. On the other hand, the compounds are anti-angiogenic, anti-proliferative, and pro-apoptotic. Thalidomide analogues have been used as inhibitors of alpha glucosidase and could be potential drugs for diabetes treatment. In this review, we explore the current trend of the different structures, the new patents, and the possible new applications in different pathologies.
Subject(s)
Angiogenesis Inhibitors/pharmacology , Immunologic Factors/pharmacology , Thalidomide/pharmacology , Animals , Antineoplastic Agents/pharmacology , Humans , Lenalidomide , Patents as Topic , Thalidomide/analogs & derivativesABSTRACT
CD154, a member of the tumor necrosis factor receptor family, is involved in several biological responses. In the sera of systemic lupus erythematosus (SLE) patients, the levels of sCD154 have been shown to be increased, however, few reports have dealt with the biologically active tetramer. Here, we assessed the biological activity of the serum CD154 tetramer using bioassays for BC activation and production nitrite or peroxide. The patients showed a markedly increased total sCD154 serum concentration (12.5 +/- 8.2 vs. 3.9 +/- 1.2 ng/ml; p < 0.001). ba-sCD154 was significantly increased in non-treated patients (7.4 +/- 3.4 ng/ml, n = 22; p < 0.001) and patients with the highest SLE disease activity index (SLEDAI) scores (5.3 +/- 2.9 ng/ml, n = 8), but not in stable patients (1.3 +/- 1.2 ng/ml, n = 30) whose values were similar to normal healthy donors (NHD; 0.8 +/- 0.2 ng/ml). Patients with SLEDAI above 8 that recovered after successful treatment displayed significantly decreased levels of ba-sCD154. We conclude that the bioassay is a useful tool discriminating active and stable SLE, as well as non-treated patients.
Subject(s)
CD40 Ligand/blood , Lupus Erythematosus, Systemic/blood , Biomarkers/analysis , CD40 Ligand/immunology , CD40 Ligand/metabolism , Enzyme-Linked Immunosorbent Assay , Flow Cytometry , Humans , Lupus Erythematosus, Systemic/immunology , Lupus Erythematosus, Systemic/metabolism , Macrophages/immunologyABSTRACT
In patients with systemic lupus erythematosus (SLE) metabolic alterations are often observed, which may be due to either the disease, the genetic background or the treatment. We studied the serum levels of the adipokines leptin, adiponectin, resistin, visfatin and ghrelin in patients with SLE and controls. Leptin levels were lower and adiponectin, ghrelin and visfatin levels were higher in the patients. No significant differences were encountered for resistin. The values of adipokines were independent of treatment, even after correction for body mass index. Inverse correlations were found among leptin and adiponectin, ghrelin and visfatin. We conclude that adipokines are involved in the metabolic imbalance of patients with SLE.
Subject(s)
Adiponectin/blood , Ghrelin/blood , Leptin/blood , Lupus Erythematosus, Systemic/blood , Nicotinamide Phosphoribosyltransferase/blood , Resistin/blood , Adult , Body Mass Index , Female , Humans , MaleABSTRACT
Recently, a third subset of Th17 cells has been described. This T helper subset induces the release of chemokines and growth factors and causes neutrophil accumulation in several mammalian organs. Pharmacological intervention blocking Th17 generation as well as IL-17 signaling might prove useful in a variety of diseases including asthma, chronic obstructive pulmonary disease, Crohn's disease, cystic fibrosis, multiple sclerosis, psoriatic disease and rheumatoid arthritis. Here, we describe the patents that address a potential pharmacological use of promoting or targeting IL-17.
Subject(s)
Anti-Allergic Agents/therapeutic use , Autoimmune Diseases/drug therapy , Cytokines/metabolism , Hypersensitivity/drug therapy , Interleukin-17/antagonists & inhibitors , T-Lymphocytes, Helper-Inducer/drug effects , Animals , Anti-Allergic Agents/pharmacology , Autoimmune Diseases/immunology , Clinical Trials as Topic , Cytokines/immunology , Humans , Hypersensitivity/immunology , Interleukin-17/immunology , Signal Transduction/immunology , T-Lymphocytes, Helper-Inducer/immunologyABSTRACT
The pathogenesis of chronic idiopathic urticaria (CIU) is not completely understood although autoimmunity has been proposed. The aim of the study was to assess the expression of different leukocyte antigens, by flow cytometry, assaying total blood of 29 patients with CIU and of 20 sex and age matched controls. Moreover, we assessed soluble CD154 a marker of immune cell activation, predominantly memory T cells. When patients were divided depending an their response to the autologous serum skin test (ASST), three different groups were encountered: group 1 (n=11): with negative ASST-, group 2 (n=11): positive ASST (ASST+) with normal lymphocyte counts and group 3 (n=7): ASST+ with low lymphocyte counts (< 1500 cells/mm3). A significant increase in CD19+ percentage and not in the absolute count (P < 0.05) was observed in group 1 as compared to controls and to the other groups. In contrast, CD30+, CD45RO+ and CD4+/CD45RO+ percentages and biologically active soluble CD154 levels were significantly higher (P < 0.05) in group 3 as compared to group 1 or to controls. In ASST positive groups, CD45RO+ and CD4+/CD45RO+ positiveness correlates with wheal diameter. In conclusion, memory cells may play a role in these different types of patients and in understanding CIU pathogenesis.
Subject(s)
Immunologic Memory , Urticaria/immunology , Adult , Antigens, CD/immunology , Chronic Disease , Data Interpretation, Statistical , Female , Flow Cytometry , Humans , Immunophenotyping , Leukocyte Count , Lymphocyte Count , Male , Middle Aged , Skin Tests , T-Lymphocytes/immunology , Urticaria/blood , Urticaria/diagnosis , Urticaria/etiologyABSTRACT
La patogénesis de la urticaria crónica idiopática (CIU) no se conoce completamente; sin embargo, la autoinmunidad juega un papel importante en un subgrupo de pacientes. El objetivo de este estudio fue la determinación de antígenos leucocitarios en sangre total, utilizando citometría de flujo, de 29 pacientes con CIU y 20 controles de similar edad y sexo. Adicionalmente, se determinó el CD154 soluble como marcador de activación de células inmunes, predominantemente linfocitos T de memoria. Se describieron 3 grupos de pacientes de acuerdo al resultado de la prueba de suero antólogo (ASST): grupo 1: negativo (n = 11), grupo 2: prueba positiva y contaje linfocitario normal (n = 11) y grupo 3 prueba positiva y contaje linfocitario bajo (< 1500 células/mm3) (n = 7). En el grupo 1, se observó un aumento significativo (P < 0,05) en el porcentaje de células CD19+ aunque no en su número absoluto cuando se comparó con los controles y los pacientes con ASST +. En contrapartida, el porcentaje de células positivas para CD30, CD45RO y CD4/CD45RO y los niveles de CD154 soluble biológicamente activo fueron significativamente mayores (P < 0,05) en el grupo 3, en comparación con los controles y el grupo 1. Además, en los grupos con ASST positiva, los porcentajes de células CD45RO+ y CD4/CD45RO+ se correlacionan con el tamaño del habón a la ASST. En conclusión, las células de memoria pudieran jugar un papel importante en la patogénesis de la CIU.
Subject(s)
Humans , Male , Female , Immunophenotyping , Memory , Urticaria , Medicine , VenezuelaABSTRACT
La Hepatitis Autoinmune constituye una inflamación crónica del hígado caracterizada por la presencia de autoanticuerpos y de hepatitis de interfase en el examen histológico e hipergammaglobulinemia. Constituye el 11-23 por ciento de todos los casos de hepatitis crónica en USA, afecta principalmente a las mujeres, siendo el tipo I el más frecuente. Se presenta el caso de una paciente de 21 años, con perfil inmunológico compatible con una Hepatitis Autoinmune tipo 2, con autoanticuerpos antimicrosomales de Hígado-Riñón (LKM1) positivo, lo cual es de prevalencia muy baja .El hallazgo asociado de anticuerpos antimitocondriales (AMA) positivo, característico de Cirrosis Biliar Primaria, nos lleva a considerar: Síndrome de Superposición